- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 14.12. | Alpha Tau Medical up sharply as brain cancer trial begins | 3 | Globes | ||
| 10.12. | H.C. Wainwright reiterates Buy rating on Alpha Tau Medical stock | 2 | Investing.com | ||
| 10.12. | Why Did Alpha Tau Medical (DRTS) Shares Jump Over 25% In After-Hours Trading? | 2 | Benzinga.com | ||
| 09.12. | Alpha Tau Medical Ltd.: Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University | 137 | GlobeNewswire (Europe) | - First patient in the world treated with Alpha DaRT- in the brain - - According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers... ► Artikel lesen | |
| 09.12. | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 02.12. | Alpha Tau Medical Ltd.: Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer | 99 | GlobeNewswire (Europe) | JERUSALEM, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT- , today announced that the FDA... ► Artikel lesen | |
| ALPHA TAU MEDICAL Aktie jetzt für 0€ handeln | |||||
| 02.12. | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 20.11. | Alpha Tau Medical GAAP EPS of -$0.39 | 1 | Seeking Alpha | ||
| 20.11. | Alpha Tau Medical Ltd.: Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update | 1.358 | GlobeNewswire (Europe) | - Alpha DaRT pancreatic cancer patient treatments underway in U.S. multi-center pilot study - - Newly received radioactive material license for New Hampshire facility positions the Company for continued... ► Artikel lesen | |
| 20.11. | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 23.10. | Alpha Tau Medical stock holds Buy rating at H.C. Wainwright after license win | 1 | Investing.com | ||
| 21.10. | Alpha Tau Medical Ltd.: Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness | 2 | GlobeNewswire (USA) | ||
| 21.10. | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 02.09. | Alpha Tau Medical Ltd.: Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial | 3 | GlobeNewswire (USA) | ||
| 27.08. | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 11.08. | Alpha Tau Medical Ltd.: Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update | 334 | GlobeNewswire (Europe) | - FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer - - Multiple U.S. clinical... ► Artikel lesen | |
| 19.05. | Alpha Tau Medical Ltd.: Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update | 379 | GlobeNewswire (Europe) | - Interim Jan-2025 results from three trials of Alpha DaRT® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium and R&D Update Day, showing >90% disease control rate, impressive... ► Artikel lesen | |
| 28.04. | Oramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical | 651 | PR Newswire | Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology
Accelerating multiple late-stage cancer therapies... ► Artikel lesen | |
| 02.04. | Alpha Tau Medical Ltd.: Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma | 327 | GlobeNewswire (Europe) | JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BETA BIONICS | 31,690 | +8,34 % | Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 38,000 | 0,00 % | S&P Dow Jones Indices: BrightSpring Health Services Set to Join S&P SmallCap 600 | NEW YORK, Oct. 14, 2025 /PRNewswire/ -- BrightSpring Health Services Inc. (NASD: BTSG) will replace Veritex Holdings Inc. (NASD: VBTX) in the S&P SmallCap 600 effective... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 20,200 | -1,08 % | Alignment Healthcare, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| HEARTFLOW | 31,250 | +2,43 % | Hedge Fund and Insider Trading News: Ken Griffin, Warren Buffett, Israel Englander, Viking Global, Point72 Asset Management, Heartflow Inc (HTFL), Teva Pharmaceutical Industries Ltd (TEVA), and More | ||
| PRIVIA HEALTH GROUP | 24,020 | +1,61 % | Privia Health Group, Inc.: Privia Health Reports Third Quarter 2025 Financial Results | Very Strong Third Quarter and Year-to-Date Performance Across the BusinessNet Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q'24Implemented Providers +13.1% and Practice Collections +27.1%... ► Artikel lesen | |
| PROGYNY | 26,970 | 0,00 % | Progyny, Inc. - 8-K, Current Report | ||
| PROCEPT BIOROBOTICS | 34,250 | 0,00 % | Promising Growth Forecasts Leading to Analysts' Optimism for Procept Biorobotics (PRCT) | ||
| ADAPTHEALTH | 10,290 | +3,21 % | AdaptHealth: Strategische Expansion und Technologie-Investitionen als Wachstumstreiber | ||
| GENEDX | 139,93 | -0,36 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| BILLIONTOONE | 96,29 | 0,00 % | BillionToOne, Inc.: BillionToOne Reports Third Quarter 2025 Results | MENLO PARK, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are... ► Artikel lesen | |
| CASTLE BIOSCIENCES | 41,405 | +4,98 % | Castle Biosciences, Inc.: Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| LUMEXA IMAGING | 17,945 | 0,00 % | Lumexa Imaging Announces Pricing of Initial Public Offering | RALEIGH, N.C., Dec. 10, 2025 /PRNewswire/ -- Lumexa Imaging Holdings, Inc. ("Lumexa Imaging") announced today the pricing of its initial public offering of 25,000... ► Artikel lesen | |
| KESTRA MEDICAL TECHNOLOGIES | 28,010 | 0,00 % | Kestra Medical Technologies, Ltd.: Kestra Medical Technologies Reports Second Quarter Fiscal 2026 Financial Results | KIRKLAND, Wash., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported financial results for... ► Artikel lesen | |
| RXSIGHT | 12,230 | 0,00 % | RxSight, Inc. Announces Chief Financial Officer Transition | ALISO VIEJO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery... ► Artikel lesen | |
| FRESENIUS | 48,400 | -0,31 % | DAX tiefer, China schwach: US-Arbeitsmarkt, Rheinmetall, Zalando, Fresenius, Nordex, Pfizer ... | Der DAX hat am Montag einen knappen Gewinn über die Ziellinie retten können. Aus dem Handel ging er mit einem Plus von 0,2 Prozent auf 24.229,91 Zählern. Zum Start in den Dienstag dürfte er zunächst... ► Artikel lesen |
Das Unternehmen ALPHA TAU MEDICAL LTD kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 5,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALPHA TAU MEDICAL LTD finden Sie auf Wallstreet Online.